

Use of dried blood spots to measure methotrexate levels and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM)

Submission date 20/10/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 02/12/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 26/10/2015	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Methotrexate is an important drug in treating children with rheumatic disorders such as juvenile idiopathic arthritis (joint inflammation) and juvenile dermatomyositis (skin rash and muscle inflammation). Finger prick dried blood spot samples is the technique widely used in newborns for diagnosing diseases at birth. It requires collection of a few drops of blood on a card which can then be posted to a central laboratory and is very well established. We aim to develop a method for determining methotrexate levels in dried blood spot samples. This method could be used to determine patients have difficulties in absorbing methotrexate, their response to long-term methotrexate treatment, their adherence with prescribed treatment. Dried blood spot sampling is easy to perform and requires very small volumes of blood (a few drops of blood from a simple finger prick), potentially allowing parents to take samples at home, for example, to assist in the monitoring of their child. In addition, such samples are easy to store and transport, without special conditions. The method will also facilitate more research with methotrexate, which will benefit future patients.

Who can participate?

Children aged 4-16 years diagnosed with either juvenile idiopathic arthritis or juvenile dermatomyositis and prescribed methotrexate for at least 2 months.

What does the study involve?

Not provided at time of registration.

What are the possible benefits and risks of participating?

Not provided at time of registration.

Where is the study run from?

The Royal Liverpool Children's Hospital (Liverpool), Musgrave Park Hospital (Belfast) and the University College London (UCL) Institute of Child Health / Great Ormond Street Hospital for Children (GOSH) (London) (UK).

When is study starting and how long is it expected to run for?

April 2011 to April 2012.

Who is funding the study?

Arthritis Research UK.

Who is the main contact?

Abdel Qader Al Bawab
aalbawab02@qub.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mr Abdel Qader Al Bawab

Contact details

Main Campus
University Road
Belfast
United Kingdom
BT7 1NN

-
aalbawab02@qub.ac.uk

Additional identifiers

Protocol serial number

11019

Study information

Scientific Title

Use of dried blood spots to measure methotrexate levels and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM): an observational study

Study objectives

Use of dried blood spots to measure methotrexate and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Office of Research Ethics Committees of Northern Ireland, First MREC approval date 01/10/2011, ref: 10/NIR03/33

Study design

Non-randomised observational cross-sectional study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)

Interventions

We will test the possibility of developing an analytical method for the determination of methotrexate and its polyglutamate metabolites in dried blood spot samples. We will also be examining the practicality of home sampling in children.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

To determine the possibility of developing an analytical method for the determination of methotrexate and its polyglutamate metabolites in dried blood spot samples

Key secondary outcome(s)

To determine whether home sampling is practical

Completion date

01/04/2012

Eligibility

Key inclusion criteria

1. Children aged 4-16 years diagnosed with either juvenile idiopathic arthritis or juvenile dermatomyositis (confirmed by a consultant) attending the rheumatology clinic at the paediatric rheumatology outpatient clinics at three sites: the Royal Liverpool Children's Hospital (Liverpool), Musgrave Park Hospital (Belfast) and the University College London (UCL) Institute of Child Health / Great Ormond Street Hospital for Children (GOSH) (London)
2. The child is prescribed methotrexate for at least 2 months (oral or subcutaneous)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

4 years

Upper age limit

16 years

Sex

All

Key exclusion criteria

Do not meet the above inclusion criteria or if patients (or their parents/ guardians) do not wish to participate in the research

Date of first enrolment

01/04/2011

Date of final enrolment

01/04/2012

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

The Queen's University of Belfast

Belfast

United Kingdom

BT7 1NN

Sponsor information

Organisation

Arthritis Research UK (UK)

ROR

<https://ror.org/02jkpm469>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research UK (UK)

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	22/10/2015		Yes	No
HRA research summary			28/06/2023	No	No